KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Acadia Pharmaceuticals (ACAD) Return on Equity (2016 - 2025)

Historic Return on Equity for Acadia Pharmaceuticals (ACAD) over the last 16 years, with Q3 2025 value amounting to 0.3%.

  • Acadia Pharmaceuticals' Return on Equity rose 700.0% to 0.3% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.3%, marking a year-over-year increase of 700.0%. This contributed to the annual value of 0.39% for FY2024, which is 5400.0% up from last year.
  • According to the latest figures from Q3 2025, Acadia Pharmaceuticals' Return on Equity is 0.3%, which was up 700.0% from 0.28% recorded in Q2 2025.
  • Over the past 5 years, Acadia Pharmaceuticals' Return on Equity peaked at 0.35% during Q4 2024, and registered a low of 0.52% during Q4 2022.
  • Its 5-year average for Return on Equity is 0.17%, with a median of 0.3% in 2021.
  • Its Return on Equity has fluctuated over the past 5 years, first plummeted by -2200bps in 2022, then surged by 6300bps in 2024.
  • Acadia Pharmaceuticals' Return on Equity (Quarter) stood at 0.3% in 2021, then plummeted by -73bps to 0.52% in 2022, then surged by 70bps to 0.15% in 2023, then soared by 324bps to 0.35% in 2024, then fell by -13bps to 0.3% in 2025.
  • Its Return on Equity stands at 0.3% for Q3 2025, versus 0.28% for Q2 2025 and 0.31% for Q1 2025.